Cantor Fitzgerald Forecasts CMPS FY2025 Earnings

COMPASS Pathways plc (NASDAQ:CMPS) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for COMPASS Pathways in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings of ($2.05) per share for the year. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter in the prior year, the firm posted ($0.67) EPS.

CMPS has been the topic of several other reports. Maxim Group decreased their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Finally, HC Wainwright cut their price target on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a report on Friday, November 1st. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $33.60.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $3.64 on Wednesday. COMPASS Pathways has a 52-week low of $3.16 and a 52-week high of $12.75. The stock’s 50-day simple moving average is $4.24 and its 200 day simple moving average is $5.83. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The stock has a market capitalization of $249.05 million, a price-to-earnings ratio of -1.65 and a beta of 2.27.

Institutional Investors Weigh In On COMPASS Pathways

Several hedge funds have recently bought and sold shares of CMPS. Logos Global Management LP increased its holdings in shares of COMPASS Pathways by 349.3% in the 2nd quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock worth $7,001,000 after buying an additional 901,050 shares during the last quarter. Sio Capital Management LLC increased its stake in COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after acquiring an additional 621,222 shares during the last quarter. Rosalind Advisors Inc. raised its position in COMPASS Pathways by 6.5% during the third quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company’s stock valued at $4,923,000 after purchasing an additional 47,423 shares in the last quarter. Polar Asset Management Partners Inc. lifted its stake in COMPASS Pathways by 83.3% during the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after purchasing an additional 258,000 shares during the last quarter. Finally, Acuta Capital Partners LLC bought a new stake in COMPASS Pathways during the third quarter worth about $2,435,000. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.